The FDA approved Tregzi, a precision-engineered cell therapy, to improve chronic GVHD-free survival in adults undergoing allogeneic transplant. The U.S. Food and Drug Administration (FDA) has approved ...
Oncology nurse Diane Stanaway offers essential sun protection strategies as NJ prepares for the heat of the 2026 World Cup and rising skin cancer rates. As MetLife Stadium in East Rutherford, New ...
The FDA approved the BESREMi Pen for polycythemia vera, offering a simplified self-administration option to improve patient adherence and care. PharmaEssentia USA Corporation has announced that the ...
The core of this optimization strategy is the geriatric assessment. At Mount Sinai, Jakubowski noted that patients aged 65 and older — and in some cases, those 60 and older — receive a comprehensive ...
Hughes discusses managing GI toxicities and the need for research regarding GLP-1 use among breast cancer patients and ...
Nicholas Hornstein, MD, PhD discusses ctDNA in colorectal cancer, the INTERCEPT-TT trial, building Northwell's GI oncology program, and what better drugs will look like. In this episode of The ...
FDA approves sacituzumab govitecan-hziy as monotherapy and with pembrolizumab for first-line treatment of advanced triple-negative breast cancer. On June 24, 2026, the Food and Drug Administration ...
William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisberg, MD; Ulka Vaishampayan, MD, FASCO ...
The FDA approved palbociclib (Ibrance) for maintenance in HR+/HER2+ metastatic breast cancer after induction therapy, based on the PATINA trial. On June 24, the U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results